<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02216383</url>
  </required_header>
  <id_info>
    <org_study_id>3344</org_study_id>
    <secondary_id>2014-001948-37</secondary_id>
    <nct_id>NCT02216383</nct_id>
  </id_info>
  <brief_title>Intramuscular Oxytocics: A Comparison Study of Intramuscular Carbetocin, Syntocinon and Syntometrine for the Third Stage of Labour Following Vaginal Birth</brief_title>
  <acronym>IMox</acronym>
  <official_title>Intramuscular Oxytocics: A Randomised Control Trial of Intramuscular Carbetocin, Syntocinon and Syntometrine for the Third Stage of Labour Following Vaginal Birth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Bristol NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bristol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of the West of England</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal United Hospital Bath NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gloucestershire Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals Bristol NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>North Bristol NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND Around a quarter of all global pregnancy and child-birth related deaths are due to
      excessive bleeding after the birth of the baby and placenta, or &quot;post-partum haemorrhage&quot;
      (PPH). In the UK, PPH affects approximately 10% of new mothers. PPH can be extremely
      frightening for women and can cause them to need additional treatments including blood
      transfusion and removal of the womb as well as prolonging their hospital stay.

      The most common cause of PPH is an inadequately contracted womb after childbirth. Giving the
      mother an injection of &quot;uterotonic&quot; medicine following the birth of their baby can prevent
      this. It reduces the risk of PPH by 66% and this should routinely be offered to all labouring
      women.

      In the UK, the two medicines most commonly used for this purpose are Syntocinon and
      Syntometrine. Both mimic natural hormones. Syntometrine is longer acting, but a published
      review of trials comparing these two medicines concluded that Syntometrine is no better at
      preventing severe blood loss. Syntometrine is associated with more side effects including
      nausea, vomiting, and high blood pressure, and has been linked with rare, but fatal, cases of
      stroke. All guidelines therefore recommend Syntocinon for preventing PPH.

      Our group conducted a telephone survey of all maternity units in the UK, and found that 71.4%
      of units still routinely use Syntometrine. Investigators estimate that 40,000-70,000 women
      per year are experiencing distressing nausea and vomiting in the emotionally important first
      few hours following childbirth. These women are also receiving a medicine with the potential
      to cause dangerous high blood pressure.

      Carbetocin is a newer medicine, already widely used after caesarean section, but not yet
      after vaginal birth. Other studies have shown that Carbetocin is slightly better at
      preventing bleeding after birth when compared to Syntometrine, that it has fewer side effects
      than Syntometrine, and that it may be just as good as Syntocinon at preventing PPH. No
      studies have directly compared all three medicines or compared their overall cost;
      information vital to the NHS.

      METHOD Investigators propose a trial of 6285 women over 13 months, in four maternity units in
      the South-West to compare the effectiveness, side effects and cost of Syntocinon,
      Syntometrine and Carbetocin, for women having a vaginal birth.

      Women will be randomly allocated to receive one of these drugs. Women and staff will not know
      which drug they receive, so as not to influence the results collected. Staff will collect
      data such as the number of extra drugs and treatments needed and the volume of blood lost.
      Women will be asked to complete a side effects questionnaire. Investigators will perform an
      analysis of cost effectiveness once all results are available.

      AIMS Investigators aim to establish whether Carbetocin is an effective and affordable
      alternative to Syntocinon and Syntometrine, and whether it has fewer side effects for new
      mothers. Publication of our results, regardless of what they find, could potentially improve
      the birth experience of women across the UK, and support the health service in spending its
      money most effectively.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Requirement for additional uterotonic drugs</measure>
    <time_frame>From administration of prophylactic uterotonic agent to discharge from labour ward, within an expected average of 6 hours.</time_frame>
    <description>Proportion of patients requiring additional uterotonic drugs after administration of study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated volume of blood loss at delivery</measure>
    <time_frame>Within 30 minutes of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total estimated volume of blood loss</measure>
    <time_frame>From delivery until transfer from Labour Ward, within an expected average of 6 hours.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion requirement</measure>
    <time_frame>During in-patient stay, within an expected average of 2 days.</time_frame>
    <description>Number of units of blood transfused, or volume of own blood returned to patient if intraoperative cell salvage used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for any other blood products</measure>
    <time_frame>From delivery until transfer from Labour Ward, within an expected average of 2 days</time_frame>
    <description>Including fresh frozen plasma, cryoprecipitate, Factor VII (number of units of each given). The time frame for this is longer than other outcomes (such as estimated blood loss), as patients receiving blood products will have experienced a post partum haemorrhage, and will therefore be monitoring on Labour Ward for longer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the third stage of labour</measure>
    <time_frame>Up to 2 hours</time_frame>
    <description>Time from delivery of baby until delivery of placenta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for manual removal of placenta in theatre</measure>
    <time_frame>Within 2 hours of delivery</time_frame>
    <description>Yes/No answer to this question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for examination under anaesthetic in theatre</measure>
    <time_frame>From delivery until discharge from Labour Ward, within an expected average of 6 hours</time_frame>
    <description>Ie: for management of post partum haemorrhage,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal hypertension following administration of uterotonic study drug</measure>
    <time_frame>First 2 post natal hours</time_frame>
    <description>Hypertension data captured as highest systolic/diastolic blood pressure recorded in that time frame</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal hypotension following administration of uterotonic study drug</measure>
    <time_frame>First 2 post natal hours</time_frame>
    <description>Hypotension defined as BP &lt;90/60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrapartum vomiting</measure>
    <time_frame>During labour (labour lasts on average 12 hours, but can range from &lt;1hour - approximately 30hours)</time_frame>
    <description>Yes/No
By definition, labour starts when the patient is at least 3-4cm dilated with regular, painful contractions. By definition, labour ends once the placenta is delivered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for anti-emetics in first two post natal hours</measure>
    <time_frame>First two post natal hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from delivery to discharge from Labour Ward</measure>
    <time_frame>Within an expected average of 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent in recovery or higher dependency care setting</measure>
    <time_frame>Within first 2 post natal days</time_frame>
    <description>Includes High Dependency Unit care provided on Labour Ward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal experience of side effects</measure>
    <time_frame>In first two post natal hours</time_frame>
    <description>Captured using maternal side effects questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health utility score</measure>
    <time_frame>In the first 2 post natal hours</time_frame>
    <description>Generated by patient completing EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health utility score</measure>
    <time_frame>At two weeks postnatal</time_frame>
    <description>Generated by patient completing EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health utility score</measure>
    <time_frame>At four weeks post natal</time_frame>
    <description>Generated by patient completing EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total length of post natal admission</measure>
    <time_frame>Within first post natal month (with an expected average of 2 days)</time_frame>
    <description>From time of delivery to time of discharge</description>
  </other_outcome>
  <other_outcome>
    <measure>Provision of outpatient follow up for patients who experienced PPH</measure>
    <time_frame>Data captured by research team 8 weeks after discharge</time_frame>
    <description>Yes/No answer</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">6285</enrollment>
  <condition>Post Partum Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Carbetocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of 100 micrograms intramuscular Carbetocin given for active management of the third stage of labour, immediately after the birth of the baby</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Syntocinon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One dose of 10 International Units intramuscular Syntocinon given for active management of the third stage of labour, immediately after the birth of the baby</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Syntometrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One dose of 500micrograms/5 International Units intramuscular Syntometrine given for active management of the third stage of labour, immediately after the birth of the baby</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Carbetocin, listed here, is one of the of the three study drugs.</description>
    <arm_group_label>Carbetocin</arm_group_label>
    <other_name>Pabal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syntocinon</intervention_name>
    <description>The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntocinon, listed here, is one of the of the three study drugs.</description>
    <arm_group_label>Syntocinon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syntometrine</intervention_name>
    <description>The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.</description>
    <arm_group_label>Syntometrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥18 years of age at time of delivery

          -  Singleton pregnancy

          -  Vaginal birth (spontaneous and instrumental)

          -  Any gestation

        Exclusion Criteria:

          -  Significant APH (&gt;50ml) or suspected or proven placenta abruption

          -  Maternal coagulation disorder

          -  Intrauterine fetal death

          -  Patients who would decline blood products if required

          -  Known or suspected hypertensive disorders, including pre-eclampsia, pregnancy induced
             hypertension, essential hypertension (even if blood pressure well controlled)

          -  Hypertension in labour, or patients who have not had their blood pressure checked in
             labour

          -  Patients with peripheral, hepatic or cardiac disease

          -  Patients with an allergy or hypersensitivity to any of the active ingredients in
             Carbetocin, Syntometrine or Syntocinon
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Draycott, BMBS</last_name>
    <role>Study Director</role>
    <affiliation>North Bristol NHS Trust/University of Bristol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen van der Nelson, BMBS</last_name>
    <role>Study Chair</role>
    <affiliation>North Bristol NHS Trust/University of Bristol</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tim Draycott, MBBS</last_name>
    <phone>+441773232322</phone>
    <email>tim.draycott@nbt.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helen A van der Nelson, BMBS</last_name>
    <phone>+441773232322</phone>
    <email>helenvandernelson@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>North Bristol NHS Trust</name>
      <address>
        <city>Bristol</city>
        <state>Avon</state>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen van der Nelson, BMedSci BMBS</last_name>
      <phone>+441174146764</phone>
      <email>helenvandernelson@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Cathy Winter, RM</last_name>
      <phone>+441173232322</phone>
      <email>cathy.winter@nbt.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Hospitals NHS Trust</name>
      <address>
        <city>Gloucester</city>
        <state>Gloucestershire</state>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Swingler, MB ChB</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital NHS Trust</name>
      <address>
        <city>Bath</city>
        <state>Somerset</state>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Burnard, RM</last_name>
      <phone>01225 826174</phone>
      <email>sara.burnard@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2014</study_first_submitted>
  <study_first_submitted_qc>August 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2014</study_first_posted>
  <last_update_submitted>March 22, 2016</last_update_submitted>
  <last_update_submitted_qc>March 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post partum haemorrhage</keyword>
  <keyword>Active Management of Third Stage of Labour</keyword>
  <keyword>Carbetocin</keyword>
  <keyword>Syntocinon</keyword>
  <keyword>Syntometrine</keyword>
  <keyword>Birth experience</keyword>
  <keyword>Labour</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Carbetocin</mesh_term>
    <mesh_term>Syntometrine</mesh_term>
    <mesh_term>Ergonovine</mesh_term>
    <mesh_term>Oxytocics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

